Hundred Years of Insulin: The Possibility of Development of Oral Dosage Form

سال انتشار: 1400
محل انتشار: مجله تحقیقات دارویی ابن سینا، دوره: 2، شماره: 2
کد COI اختصاصی: JR_AJPR-2-2_007
زبان مقاله: انگلیسی
تعداد مشاهده: 120

نویسندگان

Molecular Pharmacology and Herbal Drug Research Laboratory, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-۱۰۰۰, Bangladesh

Arifa Sultana

Molecular Pharmacology and Herbal Drug Research Laboratory, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-۱۰۰۰, Bangladesh

Fahmida Yesmin

Molecular Pharmacology and Herbal Drug Research Laboratory, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Dhaka, Dhaka-۱۰۰۰, Bangladesh

Tahmina Akter

Department of Physiology, Dhaka Medical College, Dhaka ۱۰۰۰, Bangladesh

چکیده

Diabetes is one of the major medical problems in the world. The discovery of insulin was a milestone in the history of medical science. This legendary invention has completed ۱۰۰ years of its journey. Through this ۱۰۰-year journey, many important events have taken place, and many modifications have been made to make it convenient for commercialization and patient compliance. After the antidiabetic activity of the pancreatic extract was discovered, the bovine and pork insulin came into use. Then, recombinant human insulin was discovered. Now long-acting to rapid-acting insulin forms are available (e.g., insulin pens, insulin pumps, and the like), and different systems are in use to deliver them to the body, but all these insulins are in invasive dosage forms and have some disadvantages, too. As we are using the oral form of most medicines, we prefer the oral form of insulin. Therefore, the concern is now to develop the oral dosage form of insulin. Some proposed oral dosage forms are at different stages of the clinical trial such as classical dosage forms, enzyme inhibitors, unnatural amino acids, nanoparticles, cell-penetrating peptides, and so on. Since the oral forms of insulin create some limitations and confusion, further research is required to solve these problems. Accordingly, the aim of the review was to predict the possibility of developing marketable oral insulin.

کلیدواژه ها

Oral insulin, ۱۰۰ years of insulin , Diabetes, Current forms of insulin, Pancreas, Recombinant technology

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.